Reuters: Regulatory News: FDA reviewers say Titan drug results not as strong as hoped

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA reviewers say Titan drug results not as strong as hoped Mar 19th 2013, 13:00 March 19 | Tue Mar 19, 2013 9:00am EDT March 19 (Reuters) - Titan Pharmaceuticals Inc's experimental drug to treat opioid addiction was shown to be more effective than placebo in a clinical trial, but the results were not as strong as might be hoped, reviewers for the U.S. Food and Drug Administration said in documents published on Tuesday. The reviewers' commentary was published on the FDA's website ahead of an advisory panel meeting to be held on Thursday. The reviewers said results of the trial prompt speculation that Titan's drug needs to be given at a higher dose and they asked the panel to advise on whether the company should explore dosing further before the product is approved.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions